Pricing, Early Access Strategy and Launch planning
Objectives: To assess opportunities for pre-approval use (PAU/early access) and pricing
Therapy Area: Severe hepatic veno-occlusive disease
Client: USA pharma company
Product/Technology: Drug
Scope: 8 countries (EU5, Japan, Australia, S.Korea)
Our Workplan: Developed workplan based on secondary research to explore potential commercialisation and regulatory issues in order to assess in which countries PAU may be possible, at what price level and what the associated considerations would be.
Project Duration: 10 weeks
Outcome: Report summarising findings and recommendations + results presentation meeting. 1 year after report submitted, client contacted us to pass on their heartfelt thanks as the course of action and programme that we recommended had been a tremendous success, making a huge difference for the company, which had now achieved sales of $2.5m on the back of our recommendations. They had reviewed our report to compare what we said would happen with what had actually happened, and our team was 100% correct!
Case Studies
TESTIMONIALS
“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”
Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.
“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”
Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma
“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
